Co-Authors
This is a "connection" page, showing publications co-authored by Behnood Bikdeli and Manuel Monreal.
Connection Strength
2.124
-
Cerebral Venous Sinus Thrombosis in the U.S. Population, After Adenovirus-Based SARS-CoV-2 Vaccination, and After COVID-19. J Am Coll Cardiol. 2021 07 27; 78(4):408-411.
Score: 0.237
-
Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinical Trial. JAMA. 2021 04 27; 325(16):1620-1630.
Score: 0.236
-
Intermediate-Dose versus Standard-Dose Prophylactic Anticoagulation in Patients with COVID-19 Admitted to the Intensive Care Unit: 90-Day Results from the INSPIRATION Randomized Trial. Thromb Haemost. 2022 Jan; 122(1):131-141.
Score: 0.235
-
Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19: JACC State-of-the-Art Review. J Am Coll Cardiol. 2021 04 20; 77(15):1903-1921.
Score: 0.234
-
Incidence of VTE and Bleeding Among Hospitalized Patients With Coronavirus Disease 2019: A Systematic Review and Meta-analysis. Chest. 2021 03; 159(3):1182-1196.
Score: 0.228
-
Presenting Characteristics, Treatment Patterns, and Outcomes among Patients with Venous Thromboembolism during Hospitalization for COVID-19. Semin Thromb Hemost. 2021 Jun; 47(4):351-361.
Score: 0.227
-
Intermediate versus standard-dose prophylactic anticoagulation and statin therapy versus placebo in critically-ill patients with COVID-19: Rationale and design of the INSPIRATION/INSPIRATION-S studies. Thromb Res. 2020 12; 196:382-394.
Score: 0.226
-
Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research. Thromb Haemost. 2020 Jul; 120(7):1004-1024.
Score: 0.221
-
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020 06 16; 75(23):2950-2973.
Score: 0.219
-
Bleeding risk in hospitalized patients with COVID-19 receiving intermediate- or therapeutic doses of thromboprophylaxis. J Thromb Haemost. 2021 08; 19(8):1981-1989.
Score: 0.059